Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Sales (2016 - 2025)

CytomX Therapeutics' Return on Sales history spans 12 years, with the latest figure at 39.98% for Q4 2025.

  • For Q4 2025, Return on Sales fell 4048.0% year-over-year to 39.98%; the TTM value through Dec 2025 reached 0.23%, down 46.0%, while the annual FY2025 figure was 0.23%, 46.0% down from the prior year.
  • Return on Sales reached 39.98% in Q4 2025 per CTMX's latest filing, down from 2.39% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.5% in Q4 2024 to a low of 39.98% in Q4 2025.
  • Average Return on Sales over 5 years is 3.12%, with a median of 0.35% recorded in 2024.
  • Peak YoY movement for Return on Sales: skyrocketed 340bps in 2023, then crashed -4048bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 3.13% in 2021, then surged by 86bps to 0.44% in 2022, then skyrocketed by 107bps to 0.03% in 2023, then skyrocketed by 1475bps to 0.5% in 2024, then tumbled by -8169bps to 39.98% in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Return on Sales are 39.98% (Q4 2025), 2.39% (Q3 2025), and 0.01% (Q2 2025).